ICANOMAB

IcanoMAB is a private Biotech company focusing on the pre-clinical and development of precision canonical antibodies for the treatment of cancer, immune-system related diseases, and Covid-19. The company is developing its proprietary clinical candidates to exploit novel approaches improving clinical outcomes in immuno-oncology, solid tumors and immunology, and inflammation.